LGC Capital (TSXV:LG) shared an update with shareholders on the construction of its Tricho-Med’s cannabis growing facility in Brownsburg, Quebec.

As quoted in the press release:


Tricho-Med Expansion Plan

Tricho-Med has acquired 18 acres of additional land in close proximity to its site in Brownsburg, Quebec. The company now has the potential for a five-fold increase to its production capacity, compared to its original planned capacity at the time of the agreement with LGC in January 2018. This increase is further supported by the past purchase of approximately 20 acres of land adjacent to the facility currently under construction.

Tricho-Med plans to aggressively expand with a second facility beside its initial 34,000 square foot indoor growing operation, and it will be approximately 600,000 square feet. It will be a fully enclosed one-level building with potential for 475,000 square feet of flowering space. The combined facilities will have the potential to grow over 60,000 [kilograms] equivalent per year of dry cannabis and extracted products, based on actual industry observed yields of 30 grams per square foot per cycle when using the same production methods as Tricho-Med. All Tricho-Med products will be produced to strict Health Canada and EU-GMP standards for the domestic and international medical cannabis markets.

Click here to read the full press release.

Source: www.newswire.ca

The legalisation of medicinal cannabis in Australia, along with the decriminalisation of cannabis in the Australian Capital Territory, is creating opportunities for the export market.

But what type of cannabis products are being exported from Australia and where are they going?

Read on for a look at Australia’s cannabis export market, from how it started up, where the country sends its cannabis products and what could be next as the country’s marijuana space develops.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of Sunnyside Philadelphia, its fourth dispensary in Pennsylvania. The medical-only cannabis store is located at 1221 Chestnut St. in Philadelphia. It is in the former historic Cathay Tea Garden Restaurant building which is centrally located and steps away from the heart of downtown. Cresco’s other Sunnyside dispensaries are in Butler, Pittsburgh and New Kensington.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005212/en/

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness Company offering premium probiotic supplements and products containing CBD, announces that it has promoted Maria Leal, the Company’s Vice President and Controller, to Interim Chief Financial Officer.

Ms. Leal holds a CPA and an MBA and has a strong track record in financial management having served in various senior financial accounting positions during her more than 20-year career. Ms. Leal has been with HempFusion since July 2019 and has been instrumental in all financial reporting aspects for the Company.

Keep reading... Show less

Centurion to acquire a Disruptive Water-Soluble Cannabinoid Technology Platform Delivering Rapid Onset, Increased Bioavailability, Premium Taste Profiles and Highly Competitive Cost Structure

Centurion Minerals Ltd. (TSXV: CTN) (“Centurion”, or the “Company”) wishes to provide an update on its previously announced Amalgamation Agreement (the “Agreement”), with HAI Beverages Inc. (“HAI”), whereby Centurion is acquiring 100% of the outstanding shares and assets of a wholly-owned subsidiary of HAI (“NewHAI”) in exchange for common shares of Centurion (the “Acquisition” or “Transaction”). NewHAI holds all material assets of HAI and the Acquisition will constitute a reverse take-over (“RTO”) of the Company.

Keep reading... Show less

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has received approval to graduate  to Tier 1 Issuer status on the TSX Venture Exchange (the “TSXV”), effective June 18, 2021 .

Keep reading... Show less